July 2015, Volume :115 Number 7 , page 24 - 25 [Buy]
Join NursingCenter to get uninterrupted access to this Article
Have a coupon or promotional code? Enter it here:
When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.
* Filgrastim-sndz (Zarxio) is the first biosimilar product approved in the United States. It has been determined to be biosimilar to filgrastim (Neupogen).
Join NursingCenter on Social Media to find out the latest news and special offers
© 2021 Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved. – Terms & Conditions – Privacy Policy – Disclaimer -- v7.7.7